# Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Source: https://onco.cc/trials/nct05935748/  
OnCo record `nct05935748` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of NKT2152 run by NiKang Therapeutics, Inc., terminated.

## Summary

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) is a phase 2 interventional study registered as NCT05935748 by NiKang Therapeutics, Inc., with 18 participants enrolled, started 2023-07-28, primary completion reached 2025-06-30. Conditions recorded: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases. Interventions recorded: NKT2152, palbociclib, sasanlimab. Reason given for stopping: This study was terminated as a result of Sponsor portfolio reprioritization.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05935748
- Phase: 2
- Setting: A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Sponsor: NiKang Therapeutics, Inc.
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT05935748: https://clinicaltrials.gov/study/NCT05935748

## Connected records

- cancers: [Clear cell renal cell carcinoma](https://onco.cc/cancers/clear-cell-rcc/)
- drugs: [NKT2152](https://onco.cc/drugs/nkt2152/)
- companies: [NiKang Therapeutics](https://onco.cc/companies/nikang-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05935748.json